DP
David Pernock
Pres & Chief Operating Officer

David Pernock insider trades: Eagle Pharmaceuticals (EGRX) stock purchases

Pres & Chief Operating Officer, Eagle Pharmaceuticals Last trade May 19, 2017 32 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2013
4
Companies
last trade 2017

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 19, 2017EGRX↑ Buy$20K
May 16, 2017EGRX↑ Buy$16K
Mar 21, 2017EGRX↑ Buy$5K
Mar 9, 2017EGRX↑ Buy$35K
Dec 2, 2016FCSC↑ Buy$46K
Nov 13, 2015FCSC↑ Buy$15K
Aug 11, 2015FCSC↑ Buy$23K
May 13, 2015FCSC↑ Buy$71K
Dec 12, 2014FCSC↑ Buy$13K
Nov 20, 2014FCSC↑ Buy$13K
Jun 5, 2014FCSC↑ Buy$37K
Nov 21, 2013FCSC↑ Buy$37K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About David Pernock's insider trades

David Pernock is Pres & Chief Operating Officer at Eagle Pharmaceuticals (EGRX). Since Nov 21, 2013, David has reported 12 open-market purchases worth $331K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (16 filings), shares withheld for taxes (6 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EGRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.